



at XLIII ERA/EDTA - Glasgow 2006  
Sunday 16 July 2006

Invitation

genzyme  
RENAL

# Symposia

Over the past years, the Genzyme Symposia have earned themselves a reputation for providing valuable clinical information and facilitating discussion amongst experts on its significance in the treatment of patients affected by Chronic Kidney Disease (CKD).

This year it is our pleasure to invite you for our two symposia that will take place on Sunday, 16th July 2006, in the Lomond Auditorium.

The lunch symposium from 12:00h to 13:30h will focus on improving outcomes in patients with CKD. The symposium will start off with a discussion on the risk factors for cardiovascular disease in CKD patients, as well as how disorders in mineral metabolism in those patients have led to a change in perceived risk factors. Subsequently data from a one year bone biopsy study will be presented, looking into the effects of phosphate binders on bone turnover and bone mineralisation in CKD patients on dialysis. Finally the relation between vascular calcification

and patients' outcomes will be addressed, as well as how outcomes might be improved.

During our evening symposium, from 18:30h to 20:00h the emphasis will be on Fabry nephropathy and Fabry induced CKD.

In this symposium, the role of the nephrologist in the field of clinical risk stratification and therapeutic interventions in metabolic nephropathies will be highlighted.

Next to the latest information on disease progression in metabolic nephropathies you will be informed about specific pathophysiological measures aiding diagnosis of Fabry disease. Another focus will be a discussion on treatment expectations in relation to renal disease progression in Fabry disease.

We look forward to welcoming you to our symposia and at our booth. See you in Glasgow!

**Monday 16 July 2006**

12:00-13:30

Lomond Auditorium

**Can we improve outcomes in chronic kidney disease?**

What is the evidence for improving outcomes in CKD stage 5?

Dr David Goldsmith, UK

Impact of phosphate binders on bone histomorphometry;  
results of a one-year bone biopsy study

Dr Anibal Ferreira, Portugal

Cardiovascular calcification in CKD stage 5 -  
can we alter progression?

Dr Geoffrey Block, USA

**Sunday 16 July 2006**

18.30-20.00

Lomond Auditorium

**New insights in metabolic nephropathies**

Disease progression in metabolic nephropathies

Prof B. Brenner, USA

Successful interventions in metabolic nephropathies

Prof C. Wanner, Germany

Preserving the renal function in Fabry patients

Dr S. Waldek, UK